Approved Drug Label (PDF)
5
Warnings and Precautions
5.2 Local Irritation and Hypersensitivity Reactions
Additions and/or revisions underlined:
Local
tolerability reactions (including blistering and skin desquamation) and
hypersensitivity adverse reactions
(including
urticaria)
have been observed with topical tazarotene. Application of AVAGE Cream …
6
Adverse Reactions
6.1 Clinical Trials Experience
Additions and/or revisions underlined:
Overall, 20/567
(3.5%) subjects in the AVAGE Cream group and 16/564 (2.8%) subjects in the
vehicle group reported adverse events (including edema, irritation, and
inflammation) directly related to the eye or eyelid. The majority of these
conditions were mild.
Newly added subsection:
6.2 Postmarketing Experience
The following
adverse reactions have been identified during postapproval use of tazarotene.
Because these reactions are reported voluntarily from a population of uncertain
size, it is not always possible to reliably estimate their frequency or
establish a causal relationship to drug exposure.
Skin and
subcutaneous tissue disorders: blister, dermatitis, urticaria, skin
exfoliation, skin discoloration (including skin hyperpigmentation or skin
hypopigmentation), swelling at or near application sites, and pain.
17 PCI/PI/MG (Patient Counseling Information/Patient Information/Medication Guide)
PATIENT COUNSELING INFORMATION
Important
Administration Instructions
Additions and/or revisions
underlined:
AVAGE Cream is for topical use only. Do not apply to eyes and mouth,
or other mucous membranes. The cream may cause severe redness, itching,
burning, stinging, and peeling. Avoid
accidental transfer of AVAGE Cream into eyes, mouth, or other mucous
membranes. If contact with mucous
membranes occurs, rinse thoroughly with water. Seek medical attention if eye
irritation continues. Wash hands thoroughly after applying AVAGE Cream.
Approved Drug Label (PDF)
4
Contraindications
AVAGE
Cream is contraindicated in: (Additions
underlined)
5
Warnings and Precautions
5.1 Embryofetal Toxicity
(additional information from PLR Conversion)
Based
on data from animal reproduction studies, retinoid pharmacology and the potential
for systemic
absorption,
AVAGE Cream may cause fetal harm when administered to a pregnant female and is
contraindicated during pregnancy. Safety in pregnant females has not been
established. The potential risk to the
fetus outweighs the potential benefit to the mother from AVAGE Cream use during
pregnancy; therefore, discontinue AVAGE Cream as soon as pregnancy is
recognized. Tazarotene elicits
malformations and developmental effects associated with retinoids after topical
and oral administration to pregnant rats and rabbits during organogenesis. However, limited case reports of pregnancy in
females enrolled in clinical trials for AVAGE Cream have not reported a clear
association with tazarotene and major birth defects or miscarriage risk.
…
tazarotene is a teratogenic substance in animals, and it is not known
what level of exposure is required for teratogenicity in humans.
Advise
pregnant
females of the potential risk to a fetus. Obtain a pregnancy test within 2 weeks
prior to AVAGE Cream therapy.
Initiate AVAGE Cream therapy during a menstrual period. Advise
females of reproductive potential to use effective contraception during
treatment with AVAGE Cream.
5.2 Local Irritation and Hypersensitivity Reactions
Local
tolerability reactions and hypersensitivity adverse reactions have been
observed with topical tazarotene.
…If these adverse reactions
occur, discontinue the medication until the integrity of the skin
is restored, or
reduce the dosing to
an interval the patient can
tolerate …
Closely
monitor the frequency of application by carefully observing the therapeutic
response and skin tolerance. (additions
underlined)
5.3 Photosensitivity and Risk of Sunburn
Because
of heightened burning susceptibility, minimize exposure to ultraviolet
rays (including sunlight and sun lamps) during the use of AVAGE
Cream … Advise patients with sunburn not to use AVAGE Cream until the
sunburn is fully recovered … Avoid using AVAGE Cream if the patient
is also taking drugs known to be photosensitizers (e.g., thiazides,
tetracyclines, fluoroquinolones, phenothiazines, sulfonamides) because of the
increased possibility of augmented photosensitivity. (additions underlined)
5.4 Lentigo Maligna (new subsection added)
Some facial pigmented lesions are not lentigines, but
rather lentigo maligna, a type of melanoma.
Before application of AVAGE Cream, carefully assess facial
pigmented lesions of concern by a qualified physician (e.g., dermatologist) to exclude a diagnosis of
lentigo maligna.
6
Adverse Reactions
The
following serious adverse reactions are discussed in more detail in other
sections of the labeling:
6.1 Clinical Trials Experience
The
most frequent adverse reactions reported with AVAGE Cream, 0.1% that
occurred in greater than 10% of subjects, included desquamation, erythema,
burning sensation, and dry skin (in descending order). Reactions that occurred
in 1 to 10% of subjects, included skin
irritation, pruritus, irritant contact dermatitis, stinging, rash, and
cheilitis (in descending order). Common adverse events that occurred at
a rate of at least 1% and at a higher rate in the AVAGE Cream group than
in the vehicle group in the clinical trials are presented in the
following table. (additions underlined)
TABLE
OF ADVERSE EVENTS SEEN IN 24-WEEK CLINICAL TRIALS WITH AVAGE CREAM 0.1% (Additional table; please
refer to label)
A
few subjects reported adverse events at Week 0; however, for patients who were
treated with AVAGE Cream, the highest number of new reports for each adverse
event was at Week 2.
When
combining data from the two trials, 5.3% of subjects in the AVAGE Cream group
and 0.9% of subjects in the vehicle group discontinued because of adverse
events.
Overall,
20/567 (3.5%) subjects in the AVAGE Cream group and 16/564 (2.8%) subjects in
the vehicle group reported adverse events (including edema, irritation, and
inflammation) directly related to the eye or eyelid.
The
majority of these conditions were mild.
8
Use in Specific Populations
8.1 Pregnancy
(PLLR conversion)
Risk Summary
Based on data from animal reproduction studies,
retinoid pharmacology, and the potential for systemic absorption, AVAGE Cream
may cause fetal harm when administered to a pregnant female and is
contraindicated during pregnancy. Safety
in pregnant females has not been established.
The potential risk to the fetus outweighs the potential benefit to the
mother from AVAGE Cream during pregnancy; therefore, AVAGE Cream should be
discontinued as soon as pregnancy is recognized. Limited case
reports of pregnancy in females enrolled in clinical trials for AVAGE Cream
have not established a clear association with tazarotene and major birth
defects or miscarriage risk. Because the
exact timing and extent of exposure in relation to the gestational age are not
certain, the significance of these findings is unknown.
In animal reproduction studies with pregnant rats,
tazarotene dosed topically during organogenesis at 2times the maximum systemic
exposure in subjects treated with the maximum recommended human dose (MRHD) of
tazarotene cream, 0.1% resulted in reduced fetal body weights and reduced
skeletal ossification. In animal
reproduction studies with pregnant rabbits dosed topically with tazarotene gel
at 26 times the maximum systemic exposure in subjects treated with the MRHD of
tazarotene cream, 0.1%, there was a single incident of known retinoid
malformations, including spina bifida, hydrocephaly, and heart anomalies.
In animal reproduction studies with pregnant rats
and rabbits, tazarotene dosed orally during organogenesis at 2 and 52 times,
respectively, the maximum systemic exposure in subjects treated with the MRHD
of tazarotene cream, 0.1% resulted in malformations, fetal toxicity,
developmental delays, and/or behavioral delays. In pregnant rats,
tazarotene dosed orally prior to mating through early gestation resulted in
decreased litter size, decreased numbers of live fetuses, decreased fetal body
weights, and increased malformations at doses approximately 7 times higher than
the maximum systemic exposure in subjects treated with the MRHD of tazarotene
cream, 0.1%.
The background risk of major birth defects and
miscarriage for the indicated population is unknown. Adverse outcomes in pregnancy occur
regardless of the health of the mother or the use of medications. In the U.S. general population, the estimated
background risk of major birth defects and miscarriage in clinically recognized
pregnancies is 2-4% and 15-20%, respectively.
Data
Animal Data
In rats, a tazarotene 0.05% gel formulation dosed
topically during gestation days 6 through 17 at 0.25 mg/kg/day, which
represented 2 times the maximum systemic exposure in subjects treated with the
MRHD of tazarotene cream, 0.1% (i.e.,
2 mg/cm2 over a 15% body surface area), resulted in reduced fetal body
weights and reduced skeletal ossification. Rabbits dosed topically with 0.25
mg/kg/day tazarotene gel, which represented 26 times the maximum systemic exposure
in subjects treated with the MRHD of tazarotene cream, 0.1%, during gestation days 6 through 18, had a
single incident of known retinoid malformations, including spina bifida,
hydrocephaly, and heart anomalies.
When tazarotene was given orally to animals,
developmental delays were seen in rats, and malformations and
post-implantation loss were observed in rats and rabbits at doses representing
2 and 52 times, respectively, 0.1% atthe maximum systemic exposure seen
in subjects treated with the MRHD of tazarotene cream, 0.1%.
In female rats orally administered 2 mg/kg/day of
tazarotene from 15 days before mating through gestation day
7, a7, which represented 7 times the maximum
systemic exposure in subjects treated with the MRHD of tazarotene cream, 0.1%, classic
developmental effects of retinoids were observed including decreased number of
implantation sites, decreased litter size, decreased numbers of live fetuses,
and decreased fetal body weights. A low incidence of retinoid-related
malformations was observed at that
dose.
In a pre- and postnatal
development toxicity study, topical administration of tazarotene gel (0.125
mg/kg/day) to pregnant female rats from gestation day 16 through lactation day
20 reduced pup survival, but did not affect the reproductive capacity of the
offspring. Based on data from another
study, the maximum systemic exposure in the rat would be equivalent to the maximum
systemic exposure in subjects treated with the MRHD of tazarotene
cream, 0.1%.
8.2 Lactation
(PLLR conversion)
Risk
Summary
There
is no information regarding the presence of tazarotene in human milk, the
effects on the breastfed infant, or the effects on milk production. After
single topical doses of 14C-tazarotene gel to the skin of lactating rats,
radioactivity was detected in rat milk.
The lack of clinical data during lactation precludes a clear
determination of the risk of AVAGE Cream to an infant during lactation;
therefore, the developmental and health benefits of breastfeeding should be
considered along with the mother’s clinical need for AVAGE Cream and any
potential adverse effects on the breastfed child from AVAGE Cream or from the
underlying maternal condition.
8.3 Females and Males of Reproductive Potential
(PLLR conversion)
Pregnancy
Testing
Pregnancy
testing is recommended for females of reproductive potential within 2 weeks
prior to initiating AVAGE
Cream therapy which should begin during a menstrual period.
Contraception
Females
Based
on animal studies, AVAGE Cream may cause fetal harm when administered to a
pregnant woman. Advise females of reproductive potential to use effective
contraception during treatment with AVAGE Cream.
8.4 Pediatric Use
The
safety and efficacy of tazarotene cream have not been established in
patients under the age of 17 years with facial fine wrinkling, facial
mottled hyper- and hypopigmentation, and benign facial lentigines. (additions
and/or underlined)
8.5 Geriatric Use
In
the studies of facial fine wrinkling, facial mottled hyper- and hypopigmentation,
and benign facial lentigines, 44 male subjects and 180
female subjects out of the total population of 1131 subjects were
older than 65 years of age. No overall differences in safety or
effectiveness were observed between these subjects and younger subjects, and
other clinical experience has not identified differences in responses
between the elderly and younger subjects, but greater sensitivity of
some older individuals cannot be ruled out.
17 PCI/PI/MG (Patient Counseling Information/Patient Information/Medication Guide)
Patient Counseling Information
Embryofetal
Toxicity
Inform females of reproductive
potential of the potential risk to a fetus. Advise these patients to use effective
contraception during treatment with AVAGE Cream. Advise patients to inform
their healthcare provider of a known or suspected pregnancy.
Photosensitivity
and Risk of Sunburn
Advise patients to avoid excessive sun exposure and to use of sunscreens and protective measures
(hat, visor).
Advise patients to avoid using AVAGE if also taking
other medicines may increase sensitivity to sunlight.
Important
Administration Instructions
Advise patients of the following:
Use AVAGE Cream on the face once per day, at bedtime.
Avoid contact with the eyes and mouth. The cream may cause severe redness,
itching, burning, stinging, and peeling.
Gently wash face with a mild soap before applying the cream.
Dry skin before applying the cream.
Apply only a small pea sized amount (about 1/4 inch or 5 millimeter
diameter) to lightly cover the entire face.
Apply emollients or moisturizers before or after tazarotene cream and
ensure that the first cream or lotion has absorbed into the skin and dried
completely.
In the morning, apply a moisturizing sunscreen.
Patient Information
Extensively updated;
please refer to label.
Other
PLR conversion; please refer to label.